Finance

Lists
KPTI:NASDAQ
Karyopharm Therapeutics Inc
0,64 $
-0,75%
(-0,0049) 1D
0,64 $
-1,09% (-0,0070)
Pre-market
Closed: 7 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
0,65 $
High
0,69 $
Low
0,62 $
Mkt. cap
14,63 մլն
Avg. vol.
1,46 մլն
Volume
75,00
52-wk high
10,99 $
52-wk low
0,62 $
EPS
-12,84 $
Beta
1,04
Shares outstanding
22,68 մլն
No. of employees
228
Open
0,65 $
High
0,69 $
Low
0,62 $
Mkt. cap
14,63 մլն
Avg. vol.
1,46 մլն
Volume
75,00
52-wk high
10,99 $
52-wk low
0,62 $
EPS
-12,84 $
Beta
1,04
Shares outstanding
22,68 մլն
No. of employees
228
News stories
From web sources and news partners
About Karyopharm Therapeutics Inc
CEO-
Employees228
Founded2008
HeadquartersՆյութոն, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Websitekaryopharm.com
Analyst ratings
Based on 6 analysts giving stock ratings to KPTI in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current 0,64 $
11,00 $ (+1 605,43%)
Average
6,54 $ (+913,95%)
Lowest
3,00 $ (+365,12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
3,68 $
+470,5%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Maintained
8,00 $
+1 140,3%
08/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
11,00 $
+1 605,4%
07/31/2026
Colleen M. Kusy
Robert W. Baird
Hold
Downgraded
-
-
07/31/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
7,00 $
+985,3%
07/31/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
3,00 $
+365,1%
07/31/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
7,00 $
+985,3%
05/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
28,00 $
+4 241,1%
03/09/2026
Last report
13 օգս, 2026 թ.
Fiscal period
Q2 2026
-2,32 $ / -1,39 $
-66,91%miss
Revenue / Est. (USD)
33,43 մլն / 32,19 մլն
+3,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
44,04 մլն
34,08 մլն
35,07 մլն
33,43 մլն
Cost of goods sold
32,66 մլն
-96,47 մլն
35,14 մլն
30,04 մլն
Cost of revenue
32,66 մլն
-96,47 մլն
35,14 մլն
30,04 մլն
Research and development expenses
-
125,62 մլն
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,61 մլն
22,77 մլն
26,68 մլն
25,92 մլն
Operating expense
26,61 մլն
148,39 մլն
26,68 մլն
25,92 մլն
Total operating expenses
59,26 մլն
51,92 մլն
61,83 մլն
55,96 մլն
Operating income
-15,22 մլն
-17,84 մլն
-26,76 մլն
-22,53 մլն
Other non operating income
-7,42 մլն
-10,04 մլն
16,41 մլն
-32,08 մլն
EBT including unusual items
-33,09 մլն
-102,26 մլն
-22,39 մլն
-67,02 մլն
EBT excluding unusual items
-33,09 մլն
-39,90 մլն
-22,39 մլն
-67,02 մլն
Income tax expense
34,00 հզր
-67,00 հզր
1,00 հզր
-
Effective tax rate
-0,10%
0,07%
-
-
Other operating expenses
-
-
-
-
Net income
-33,13 մլն
-102,20 մլն
-22,39 մլն
-67,02 մլն
Net profit margin
-75,21%
-299,89%
-63,86%
-200,48%
Earnings per share
-3,82
-2,23
-1,24
-2,32
Interest and investment income
553,00 հզր
607,00 հզր
511,00 հզր
722,00 հզր
Interest expense
-11,01 մլն
-12,62 մլն
-12,55 մլն
-13,14 մլն
Net interest expenses
-10,46 մլն
-12,01 մլն
-12,04 մլն
-12,42 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,10 մլն
-17,82 մլն
-26,75 մլն
-22,52 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps